Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

This study tests two targeted drug combinations — ulixertinib with cetuximab, and ulixertinib with cetuximab and encorafenib — in people with colorectal cancer that cannot be surgically removed or has spread, and who have already been treated with EGFR or BRAF-targeted therapies. **You may be eligible if...** - You have colorectal cancer that is unresectable (cannot be removed with surgery) or has spread to other parts of the body - You have already received prior treatment targeting EGFR or BRAF - You are able to provide informed consent **You may NOT be eligible if...** - You have not previously received EGFR or BRAF-directed therapy - Your cancer has not been confirmed as colorectal cancer - You have significant health conditions that would make you unable to tolerate the study drugs Talk to your doctor to see if this trial is right for you.